Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14533808 | 0.95 | — | — | |
| SCHEMBL26620 | 0.95 | — | — | |
| Ethylene SCHEMBL3936195 | 0.92 | TSHR (0.36) | FFAR3ALDH1A1TSHRSLC6A3TDP1 | |
| SCHEMBL10345897 | 0.84 | CA2 (0.34) | ALDH1A1TSHRSLC6A3TDP1CHRM1 | |
| SCHEMBL3751305 | 0.82 | CYP2D6 (0.33) | FFAR3ALDH1A1TSHRSLC6A3SLC6A2 | |
| SCHEMBL2017228 | 0.79 | — | — | |
| SCHEMBL4441348 | 0.79 | TSHR (0.38) | ALDH1A1TSHRSLC6A3SLC6A2SLC6A4 | |
| SCHEMBL323329 | 0.78 | — | — | |
| SCHEMBL29957730 | 0.78 | — | — | |
| SCHEMBL9276921 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TSHRSLC6A3TDP1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968195-B1 | PHARMACEUTICAL FORMULATION CONTAINING GLYCOSAMINOGLYCAN | AIHOL CORP (US) | 2020-08-19 | — | — | EP | claimed |
| WO-2019064090-A1 | NOVEL PHARMACEUTICAL COMPOSITION COMPRISING MEFENAMIC ACID AND OTHER ANALGESIC | ZENVISION PHARMA LLP (IN) | 2019-04-04 | — | — | WO | claimed |
| US-10220042-B2 | Modified release preparations containing oxcarbazepine and derivatives thereof | SUPERNUS PHARMACEUTICALS, INC. (US) | 2019-03-05 | — | — | US | claimed |
| US-20180098996-A1 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF | SUPERNUS PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | US | claimed |
| US-9855278-B2 | Modified release preparations containing oxcarbazepine and derivatives thereof | SUPERNUS PHARMACEUTICALS, INC. (US) | 2018-01-02 | — | — | US | claimed |
| US-20170056411-A1 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF | SUPERNUS PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | claimed |
| US-9539265-B2 | Pharmaceutical formulation containing glycosaminoglycan | AIHOL CORPORATION (US) | 2017-01-10 | — | — | US | claimed |
| US-9370525-B2 | Modified release preparations containing oxcarbazepine and derivatives thereof | SUPERNUS PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | claimed |
| US-9351975-B2 | Modified release preparations containing oxcarbazepine and derivatives thereof | SUPERNUS PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | claimed |
| EP-2968195-A1 | PHARMACEUTICAL FORMULATION CONTAINING GLYCOSAMINOGLYCAN | Aihol Corporation (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2007127630-A1 | CONTROLLED RELEASED PREPARATIONS OF OXCARBAZEPINE HAVING SIGMOIDAL RELEASE PROFILE | SUPERNUS PHARMACEUTICALS, INC (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070254033-A1 | comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles; controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration | SUPERNUS PHARMACEUTICALS, INC. | 2007-11-01 | — | — | US | claimed |
| US-20050106233-A1 | Seamless; high oil content; formed by emulsion comprising oil, water, emulsifier (polyoxyethylene glycol-sorbitan monolaurate), water-soluble monovalent/polyvalent metal salt (calcium chloride), and acid; marmelo mucilage free; gelation | FMC BIOPOLYMERS AS (NO) | 2005-05-19 | — | — | US | claimed |
| EP-1496871-A1 | POLYSACCHARIDE CAPSULES AND METHODS OF PREPARATION | FMC Biopolymer AS (NO) | 2005-01-19 | — | — | EP | claimed |
| US-6838094-B2 | Tablet containing a coated core | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-04 | — | — | US | claimed |
| WO-2003084516-A1 | POLYSACCHARIDE CAPSULES AND METHODS OF PREPARATION | FMC BIOPOLYMER AS (NO) | 2003-10-16 | — | — | WO | claimed |
| US-20030118640-A1 | Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-26 | — | — | US | claimed |
| EP-1239841-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING SODIUM AMOXYCILLINE AND POTASSIUM CLAVULANATE | SmithKline Beecham plc (GB) | 2002-09-18 | — | — | EP | claimed |
| US-6358528-B1 | FOR THERAPY OF BACTERIAL INFECTION, SUSTAINED RELEASE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-19 | — | — | US | claimed |
| WO-2001047499-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING SODIUM AMOXYCILLIN AND POTASSIUM CLAVULANATE | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | claimed |